News | January 27, 2009

SurModics, Nexeon MedSystems Collaborate to Develop Renal Artery Stent

January 28, 2009 - SurModics Inc. and Nexeon MedSystems Inc. this week signed a licensing agreement to collaborate on development of a novel stent system for the treatment of renal artery disease.

This agreement is in addition to the prior one announced in July 2007 to develop a novel stent system for coronary artery disease, which is now in clinical trials. SurModics is also an equity investor in Nexeon MedSystems.

This novel stent system for the renal arteries will incorporate SurModics' proprietary Finale Prohealing Coating technology and Nexeon’s bare metal KODIAK peripheral stent technology. Terms of the agreement were not disclosed.

Atherosclerotic renal artery disease is the most common reversible cause of secondary hypertension, affecting over 2.5 million people in the U.S. The condition can also cause atrophy of the affected kidney and even kidney failure.

Studies have shown that correction of renal artery stenosis with a stent can improve blood pressure and prevent further decline in renal function. This less invasive treatment has replaced renal bypass surgery at many institutions. However, one of the limitations of current renal stent technology is the potential for scar tissue to grow through the device and cause recalcitrant recurrence (restenosis). The solution for this problem has remained elusive.

SurModics’ Finale Prohealing Coating technology utilizes a thin layer of natural coating designed to promote rapid population of normal vessel-lining cells (endothelialization) rather than scar tissue, resulting in a healthy, functional artery.

Nexeon’s proprietary Inversion Point technology is the foundation of the company’s stent families. When applied to cobalt alloys, Inversion Point technology allows stents with dramatically lower profiles without sacrificing other important front-line stent characteristics such as radial strength, vessel coverage, and visibility.

For more information: www.surmodics.com, www.nexeonmedsystems.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Overlay Init